Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up-Reference-Cited by-同舟云学术

Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Published:2022-03 Issue:3 Volume:33 Page:244-258
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Powles T.,Bellmunt J.,Comperat E.,De Santis M.,Huddart R.,Loriot Y.,Necchi A.,Valderrama B.P.,Ravaud A.,Shariat S.F.,Szabados B.,van der Heijden M.S.,Gillessen S.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference121 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Quantified relations between exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies;van Osch;Int J Epidemiol,2016

3. Epidemiology and risk factors of urothelial bladder cancer;Burger;Eur Urol,2013

4. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance;Griffiths;J Urol,2002

5. Risk of concomitant carcinoma in situ determining biopsy candidates among primary non-muscle-invasive bladder cancer patients: retrospective analysis of 173 Japanese cases;Hara;Int J Urol,2009

Cited by 275 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Split-Dose Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Systematic Literature Review and Network Meta-Analysis;Clinical Genitourinary Cancer;2024-12

2. Novel therapeutic regimens in previously untreated metastatic urothelial carcinoma: A systematic review and bayesian network meta-analysis;Urologic Oncology: Seminars and Original Investigations;2024-11

3. Biomarkers associated with survival in patients with platinum-refractory urothelial carcinoma treated with paclitaxel;Urologic Oncology: Seminars and Original Investigations;2024-11

4. Immunotherapy Plus Chemotherapy Versus Chemotherapy Alone as First-Line Treatment for Advanced Urothelial Cancer: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials;Clinical Genitourinary Cancer;2024-10

5. Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study;Clinical Genitourinary Cancer;2024-10